AVATACE-1: Bevacizumab (Avastin) as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC) a Pilot Trial.

Trial Profile

AVATACE-1: Bevacizumab (Avastin) as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC) a Pilot Trial.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms AVATACE-1
  • Most Recent Events

    • 01 Nov 2010 Primary endpoint 'Progression-free-survival-rate' has not been met, accoridng to data presented at AASLD.
    • 01 Nov 2010 Results were presented at the 61st Annual Meeting of the Association for the Study of Liver Diseases.
    • 27 Apr 2010 Actual patient number (32) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top